Observation of the clinical effect of ganglion glycosides combined with edaravone in the treatment of patients with acute cerebral infarction

Objective To explore the clinical efficacy of ganglion glycosides combined with edaravone in the treatment of patients with acute cerebral infarction(ACI), to assess the improvement of neurological function and prognosis. Methods 240 ACI patients were selected.They were randomly divided into control group(120 cases) and observation group(120 cases) by random number table.The control group received edaravone treatment, the observation group received ganglion glycosides combined with edaravone treatment.Assessed the clinical efficacy, neurological and physical features by National Institutes of Health Stroke Scale (NIHSS), Glasgow Coma Scale score (GCS) and (Fug-Meyer, FM) score. Results The NIHSS score of the observation group after treatment was (23.71±6.08)points, which was lower than (26.50±6.12)points of the control group.The FM and GCS scores of the observation group were (15.20±1.81)points and (77.89±10.15)points respectively, which were higher than (13.29±1.77)points and (13.29±1.77)points of the control group the control group, the differences were statistically significant(t=9.14, 8.25, 10.37, all P<0.05). The total effective rates of the observation group and the control group were 75.00%(90/120) and 65.00%(78/120) respectively, the difference was statistically significant between the two groups(χ2=9.64, P<0.05). Conclusion For ACI patients, treated with ganglion glycosides on the basis of edaravone, the patients′ neurologic and limb motor function is improved significantly, the clinical efficacy and prognosis is improved significantly. Key words: Brain infarction; Gangliosides; Edaravone